![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for deve... Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development. Show more
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 28, 2024 that were previously approved by the Compensation...
Honeywell (NASDAQ:HON) – Honeywell announced the acquisition of CAES Systems for $1.9 billion, focusing on expanding its aerospace and defense technology operations. Under the leadership of...
β FDA grants traditional approval to ELEVIDYS for ambulatory Duchenne patients β FDA grants accelerated approval to ELEVIDYS for non-ambulatory Duchenne patients β Sarepta will host an investor...
Adobe (NASDAQ:ADBE) – Adobe exceeded expectations in the last quarter with revenue of $5.31 billion, above analysts’ consensus polled by FactSet of $5.29 billion. Adjusted earnings...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on May 31, 2024 (the βGrant Dateβ) that were previously approved by the...
Sarepta Therapeutics Set to Join S&P MidCap 400 PR Newswire NEW YORK, May 29, 2024 NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.48 | -0.332525112574 | 144.35 | 149.91 | 143.31 | 1161377 | 146.61842388 | CS |
4 | -13.92 | -8.82185182838 | 157.79 | 162.95 | 143.31 | 1206553 | 150.04342766 | CS |
12 | 11.32 | 8.54017351943 | 132.55 | 173.1 | 109.91 | 1939023 | 138.98354962 | CS |
26 | 23.02 | 19.0484071163 | 120.85 | 173.1 | 109.91 | 1355017 | 134.50940716 | CS |
52 | 40.13 | 38.683246578 | 103.74 | 173.1 | 55.25 | 1363826 | 115.76093732 | CS |
156 | 77.09 | 115.438754118 | 66.78 | 173.1 | 55.25 | 1171698 | 109.10784715 | CS |
260 | -4.82 | -3.24164368821 | 148.69 | 181.83 | 55.25 | 1169777 | 108.69692623 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions